As an independent, non-profit organisation which has the mission to decrease cancer deaths due to lack of knowledge, the European School of Oncology (ESO) is committed to working with all stakeholder groups to try to improve cancer outcomes. The School recognises that different industries make an important contribution to improving cancer outcomes through the development of innovative technologies including diagnostics, imaging, surgical and radiotherapy equipment, and medicines. For this reason ESO fosters on-going dialogue and collaboration with industry partners.
In July 2004 ESO established the Sharing Progress in Cancer Care (SPCC) programme in order to facilitate its interactions with industry partners. SPCC partners are required to make an annual unrestricted donation to the School. Donations from SPCC partners are pooled and used to support a number of ESO initiatives including the Masterclass in Clinical Oncology, Cancer World magazine and free or low-fee educational events. Many of these events are held in low- to middle-income countries, which are not well served by other providers of cancer education. In addition, ESO gives SPCC partners the opportunity to propose collaborative projects, which are only accepted if they are aligned with ESO's mission, have multi-sponsors and address a clear unmet educational need.
The School maintains total editorial control over the planning and execution of all ESO projects. SPCC partners may be invited to contribute ideas, as appropriate, but decisions about procedures and content are made by ESO.
Donations from SPCC partners represent no more than 25% of ESO's annual budget. The rest of ESO's funding comes from its two sustaining foundations, royalties, income from conferences and donations from individual supporters.
The companies that are currently member of the SPCC programme are:
| || || || || || || || || || || |
|• || ||AstraZeneca|| || || || || ||• || ||Lilly|
|•|| ||Boehringer Ingelheim|| || || || || ||• || ||Merck KGaA, Darmstadt, Germany|
|•|| ||Bristol-Myers Squibb|| || || || || ||•|| ||Novartis |
|•|| ||Celgene Corporation|| || || || || ||• || ||Pfizer|
|•|| ||Genomic Health|| || || || || ||•|| || Roche|
|•|| ||Helsinn|| || || || || || ||Sandoz Biopharmaceutical |
Sharing Progress in Cancer Care
Matti Aapro, Geneva
For further information please contact Daniela Mengato at firstname.lastname@example.org